Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age

Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post‐marketing surveillance data by age

Abstract Introduction Avelumab + axitinib was approved in Japan in December 2019 for the treatment of curatively unresectable or metastatic renal cell carcinoma (RCC) based on results from the JAVELIN Renal 101 trial. Materials and Methods To evaluate the safety and effectiveness of avelumab + axiti...

Full description

Saved in:
Bibliographic Details
Main Authors: Mototsugu Oya, Taito Ito, Masashi Sato, Makiko Morita, Masahiro Kajita, Norio Nonomura
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Cancer Medicine
Subjects:
checkpoint control
clinical cancer research
renal cancer
target therapy
tyrosine kinase inhibitors
Online Access:https://doi.org/10.1002/cam4.70186
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items